Lesson plan

Itasetron

Itasetron ( , ; developmental code names DAU-6215 and U-98079) is a selective serotonin 5-HT 3 receptor antagonist which was under development for the treatment of anxiety disorders, cognition disorders, nausea and vomiting, and psychotic disorders but was never marketed. It is taken orally. Itasetron was first described in the scientific literature by 1990. The drug was under development by Boehringer Ingelheim. It reached phase 3 clinical trials for nausea and vomiting and phase 2 trials for anxiety disorders.

Back to article

Article summary

Itasetron ( , ; developmental code names DAU-6215 and U-98079) is a selective serotonin 5-HT 3 receptor antagonist which was under development for the treatment of anxiety disorders, cognition disorders, nausea and vomiting, and psychotic disorders but was never marketed. It is taken orally. Itasetron was first described in the scientific literature by 1990. The drug was under development by Boehringer Ingelheim. It reached phase 3 clinical trials for nausea and vomiting and phase 2 trials for anxiety disorders.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.